Defining Immune Cell Reprogramming in Pediatric Atopic Dermatitis After Dupilumab Treatment Using High-Dimensional Spectral Flow Cytometry
Icahn School of Medicine at Mount Sinai
Icahn School of Medicine at Mount Sinai
Overview:
Eczema (also known as atopic dermatitis) is the most common skin disease in children, causing red, itchy, flaking skin that affects sleep, confidence, and quality of life. Children’s immune systems are still maturing, and recent studies suggest that eczema in younger children behaves differently than in teens or adults. Dupilumab (Dupixent) is an effective treatment that blocks allergy-related signals, but we do not know exactly how it changes immune cells in children. In this project, the trainee will study blood samples from children with eczema before and after dupilumab treatment using flow cytometry, a tool that allows researchers to analyze the number and function of millions of cells. By comparing results from younger and older children, we aim to understand how children’s immune systems change with dupilumab treatment, knowledge that could lead to more personalized, effective therapies for pediatric eczema.
Status:
This was funded through a 2025 PeDRA Emerging Investigator Research Grant.